Benign prostatic hyperplasia (BPH) is a medical condition, which is characterized by non-cancerous enlargement of prostate and it generally affects men aged more than 50 years. According to the study published in The Lancet in 2015, more than 100 million people were suffering from benign prostatic hyperplasia (BPH) globally. Drugs such as Alpha- blockers and 5α-Reductase inhibitors (5ARIs), surgery such as transurethral resection of the prostate (TURP), and minimally invasive surgeries such as implants, radiofrequency ablation, and lasers are the primary treatment options available for the disease. As surgery and minimally invasive therapy offers permanent solution, the benign prostatic surgical devices market is expected to grow significantly during the forecast period.
Market Dynamics
Increasing demand for minimally invasive therapy such as implants, prostatic stents and laser therapy are expected to be primary driving force for this market. Although implant has entered very late in benign prostatic hyperplasia market, its demand is increasing. NeoTract, Inc. received the approval for first implant for benign prostatic hyperplasia in 2010 and 2013 in Europe and U.S. respectively. This huge transaction value underlines the market opportunity for such products in developed economies such as the U.S. and European economies in short-term period and globally in long-term period. Other novel treatment options such as prostatic artery embolization (PAE) has also gained traction in recent years and its application for benign prostatic hyperplasia treatment is expected to get streamlined in near future. The introduction of novel treatments options such as PAE is expected to lead to further growth in the market. Moreover, increasing aging population, which is more prone to the disease is expected to support the growth of this market. According to Population Reference Bureau, the number of American people aged 65 years and above is expected to more than double from 46 million in 2014 to 98 million by 2060.
Key features of the study:
- This report provides in-depth analysis of benign prostatic hyperplasia surgical devices market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2016 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global benign prostatic hyperplasia surgical devices market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Olympus Corporation, Boston Scientific Corporation, Medifocus Inc., KARL STORZ SE & Co. KG, NxThera, Inc., ProArc Medical, Lisa Laser Products OHG, and Richard Wolf Gmbh
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global benign prostatic hyperplasia surgical devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the benign prostatic hyperplasia surgical devices market
Detailed Segmentation:
- Global Benign Prostatic Hyperplasia Surgical Devices Market, By Product Type:
- Resectoscopes
- Radiofrequency Ablation Devices
- Urology Lasers
- Prostatic Stents
- Implants
- Others
- Global Benign Prostatic Hyperplasia Surgical Devices Market, By End User:
- Hospitals
- Ambulatory Surgery Centers
- Global Benign Prostatic Hyperplasia Surgical Devices Market, By Geography:
- North America
- By Product Type:
- Resectoscopes
- Radiofrequency Ablation Devices
- Urology Lasers
- Prostatic Stents
- Implants
- Others
- By End User:
- Hospitals
- Ambulatory Surgery Centers
- By Country:
- Europe
- By Product Type:
- Resectoscopes
- Radiofrequency Ablation Devices
- Urology Lasers
- Prostatic Stents
- Implants
- Others
- By End User:
- Hospitals
- Ambulatory Surgery Centers
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type:
- Resectoscopes
- Radiofrequency Ablation Devices
- Urology Lasers
- Prostatic Stents
- Implants
- Others
- By End User:
- Hospitals
- Ambulatory Surgery Centers
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- By Product Type:
- Resectoscopes
- Radiofrequency Ablation Devices
- Urology Lasers
- Prostatic Stents
- Implants
- Others
- By End User:
- Hospitals
- Ambulatory Surgery Centers
- By Country:
- Brazil
- Mexico
- Rest of Latin America
- Middle East
- By Product Type:
- Resectoscopes
- Radiofrequency Ablation Devices
- Urology Lasers
- Prostatic Stents
- Implants
- Others
- By End User:
- Hospitals
- Ambulatory Surgery Centers
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type:
- Resectoscopes
- Radiofrequency Ablation Devices
- Urology Lasers
- Prostatic Stents
- Implants
- Others
- By End User:
- Hospitals
- Ambulatory Surgery Centers
- By Country:
- Central Africa
- South Africa
- North Africa
- Company Profiles
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Boston Scientific Corporation
- KARL STORZ SE & Co. KG
- Medifocus Inc.
- NxThera, Inc.
- ProArc Medical
- Lisa Laser Products OHG
- Richard Wolf Gmbh
“*” marked represents similar segmentation in other categories in the respective section.
